Macro Group Pharmaceutical S.A.E.
EEGX:MCRO1.29
EGP
-0.06
(-4.44%)
ISIN
EGS7D971C011
Return %
Stock
S&P 500
1Y
74.99
14.20
3Y
145.42
81.12
5Y
- -
68.34
Capital Structure
EGP
•
in mil. unless spec.Working Capital
EGP
•
in mil. unless spec.Growth Rates
EGP
•
in mil. unless spec.Quarterly Revenue
EGP
•
in mil. unless spec.Quarterly Earnings Per Share
EGP
•
in mil. unless spec.Quarterly Dividends Per Share
EGP
•
in mil. unless spec.Company Description
- CEO
- Khaled Kamel
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Sheraton Egypt
- IPO Date
- Feb 10, 2022
- Website
- macro-egy.com
- Similar Companies
- Business
- Macro Group Pharmaceutical S.A.E. is an Egypt-based healthcare and cosmeceuticals company primarily engaged in the development, manufacture, marketing, and distribution of cosmeceutical products, dermatological solutions, and nutraceutical dietary supplements. Founded in 2005 and headquartered in Cairo, Egypt, the company operates across specialized therapeutic and personal care segments targeting medical professionals, retail pharmacies, and consumers. The company's product portfolio is organized across several core categories, including dermatological and skincare formulations, comprising anti-scarring treatments, anti-acne preparations, skin-lightening creams, intensive moisturizers, and anti-aging serums under brands such as Scaro, Sebaclar, Melatex, and Urepar; hair care products, including therapeutic anti-hair loss treatments, revitalizing shampoos, and hair oils marketed under the Atrakta brand; oral care solutions, consisting of antiseptic and therapeutic mouthwashes and specialty toothpastes under the Orovex brand; feminine hygiene preparations, including topical cleansing and antiseptic washes under the Gold brand; sun protection products, providing broad-spectrum ultraviolet protective creams and lotions; and nutraceuticals, including vitamins, mineral formulations, and immune-support dietary supplements. In addition to proprietary branded products, the company provides toll manufacturing and contract packaging services for third-party pharmaceutical and personal care enterprises through its manufacturing facility located in Badr City, Egypt. Macro Group Pharmaceutical S.A.E. conducts its primary commercial operations in Egypt, supported by a specialized medical sales force engaging physicians across dermatology, pediatrics, gynecology, and dentistry disciplines, alongside widespread distribution to wholesale and retail pharmacies. The company also exports its formulations to regional markets across the Middle East, North Africa, and Sub-Saharan Africa, including Saudi Arabia, the United Arab Emirates, Iraq, Libya, and Sudan. In recent operational developments, Macro Group Pharmaceutical S.A.E. has expanded its product pipeline with the launch of new over-the-counter dietary supplements and specialized clinical skincare lines. The company has implemented production capacity upgrades and automation enhancements at its Badr City manufacturing complex to support rising export demand. Additionally, Macro Group has advanced its international growth strategy by entering new regional distribution partnerships across the Gulf Cooperation Council (GCC) and select African markets, while expanding its domestic commercial reach through omnichannel pharmacy partnerships and digital health platforms.